Challenges and Opportunities in Radioligand Therapy
<i>Radioligand therapy</i> (RLT) is a recent term for long established nuclear medicine practices. Although radioiodine provides the historical foundations of theranostics, the prototype RLTs include <sup>68</sup>Ga-DOTATATE and <sup>177</sup>Lu-DOTATATE, which target somatostatin receptor subtype 2 in neuroendocrine tumors, and <sup>68</sup>Ga-PSMA-617 and <sup>177</sup>Lu-PSMA-617, which target prostate cancer. There are several challenges and opportunities in the realization of precision medicine through RLT. RLT, weaponized in cancer management through advances in instrumentation and radiochemistry, is transforming the nuclear oncology landscape. Equitable access to these advanced tools remains a global consideration.
Authors
- Geoffrey Michael Currie (ORCID: https://orcid.org/0000-0002-6180-8586)
- Dale L. Bailey (ORCID: https://orcid.org/0000-0001-9154-7957)
Institutions
- The University of Sydney (AU)
- Charles Sturt University (AU)
- Baylor College of Medicine (US)
- Royal North Shore Hospital (AU)
Publication Details
- Journal
- Journal of Nuclear Medicine Technology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2967/jnmt.125.270169
- Citations
- 1
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 1.36